Sheep anti Human p53Catalog number: A145P
P53 is a transcription factor with a molecular weight of 53kDa that can inhibit cell cycle progression or induce apoptosis in response to stress or DNA damage. Disruption of the p53 signalling pathway through various mechanisms is the most common alteration in human cancer occuring in over half of all tumors. The p53 protein is short lived and expressed at low levels in normal cells but accumulates and/or is activated in cells that have undergone genotoxic damage or oncogene activation. Many tumor derived and transformed cell lines express elevated levels of mutant p53 protein.
Sheep were immunized with a GST-p53 fusion protein containing amino acids 1-393 of human p53
Product Form: Unconjugated
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
Purification Method: Ammonium Sulfate Precipitation
Concentration: See vial for concentration
Applications: Western Blot (1-10 ug/ml), Immunoprecipitation, immunostaining of formalin-fixed and paraffine embedded tissues.
Functional Analysis: Western Blotting
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature, freeze upon arrival
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
Database Name: UniProt
Accession Number: P04637
Safety Datasheet(s) for this product:
Each lane contains 50µg of total cellular protein separated by 10% SDS-PAGE. (1) Murine mutant p53; (2) murine wild-type p53; (3) wild-type p53 protein from human colorectal carcinoma cells (RKO); (4) elevated levels of human p53 protein following treatment of RKO cells with adriamycin (0.2 µm).